We compared the effects of IV tramadol(l.25 mg/kg), codeine (1 mg/kg),morphine (0.125 mg/kg), and saline on gastric emptying in 10 healthy human volunteers using a double-blind, randomized, cross-over design. Subjects received one treatment at each of four sessions, 2 wk apart. Gastric emptying was studied using the paracetamol absorption test. There were significant differences when comparing all treatments for concentration-time data (P = 0.002), peak serum paracetamol concentrations (Cmax; P < O.OOl), times at Cmax (Tmax; P = 0.003), and areas under the curves from Time 0 to 360 min (AUC,-s,,; P = 0.049). Morphine profoundly inhibited gastric emptying. Compared with morphine, the Cmax (P < O.Ol), Tmax, and AUC,-360 (P < 0.05) values for tramadol were significantly different. The Tmax value for codeine (63.3 2 11.7) was greater than that for tramadol (P = 0.034). We conclude that tramadol has a measurable but smaller inhibitory effect on gastric emptying compared with other opioids. Implications:
We compared the effects of IV tramadol(l.25 mg/kg), codeine (1 mg/kg),morphine (0.125 mg/kg), and saline on gastric emptying in 10 healthy human volunteers using a double-blind, randomized, cross-over design. Subjects received one treatment at each of four sessions, 2 wk apart. Gastric emptying was studied using the paracetamol absorption test. There were significant differences when comparing all treatments for concentration-time data (P = 0.002), peak serum paracetamol concentrations (Cmax; P < O.OOl), times at Cmax (Tmax; P = 0.003), and areas under the curves from Time 0 to 360 min (AUC,-s,,; P = 0.049). Morphine profoundly inhibited gastric emptying. Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean + Compared with morphine, the Cmax (P < O.Ol), Tmax, and AUC,-360 (P < 0.05) values for tramadol were significantly different. The Tmax value for codeine (63.3 2 11.7) was greater than that for tramadol (P = 0.034). We conclude that tramadol has a measurable but smaller inhibitory effect on gastric emptying compared with other opioids. Implications:
We compared the effect of tramadol, an unconventional opioid painkiller, on stomach emptying with that of codeine and morphine in a human volunteer study. Tramadol had a measurable but smaller effect and may have clinical and economic advantages in acute pain management compared with conventional painkillers. (Anesth Analg 1998; 87:445-9) 0 pioid analgesics have important actions on the gastrointestinal tract, including diminished propulsive contractions and delayed gastric emptying (1). Opioid medication is a major cause of delayed gastric emptying in the perioperative period, with important clinical, pharmacological, and economic implications (2). These include an increased risk of regurgitation and pulmonary aspiration of gastric contents, altered bioavailability of oral medication, and prolonged requirement for parenteral fluid and drug therapy. Therefore, the use of alternative analgesic drugs without significant effects on gastrointestinal motility may offer advantages.
Tramadol is a centrally acting analgesic with a low affinity for p-opioid receptors. It also modifies pain transmission by inhibiting neuronal noradrenaline and serotonin reuptake and stimulating serotonin release (3). IV tramadol has an analgesic potency similar to that of meperidine but is associated with less respiratory depression than conventional opioids (4). Tramadol does not increase baseline pressure or the duration, frequency, or amplitude of contractions of the bile duct sphincter in patients undergoing endoscopic retrograde cholangiopancreatography (5). It has minimal effects on gastrointestinal motor function after oral delivery (6). Tramadol may therefore have clinical and economic advantages in the management of pain in surgical and trauma patients.
There is, however, little published data comparing the effects of tramadol and other opioids on gastric emptying. A study evaluating the effect of IV tramado1 (1 "g/kg) on gastric emptying in human volunteers (7) concluded that there was no significant difference between tramadol and saline. Because parenteral opioid delivery is usual in patients most at risk of the problems associated with delayed gastric emptying, confirmation of this finding would help to define the role of tramadol in acute pain management. ANALG 1998; 87:445-9 acute pain management. The profound inhibitory effect of morphine on gastric emptying is well established. Codeine has little demonstrated effect on gastric emptying at clinical doses (8) but significantly inhibits gastric emptying at larger doses (9). The aim of this volunteer study was to compare the effects of clinical doses of IV tramadol, codeine, and morphine on gastric emptying.
Methods
After ethical committee approval, 10 nonsmoking volunteers were recruited, and informed, written consent obtained. Before the study, the volunteers' good health was confirmed by physical examination and biochemical and hematological screening. Volunteers were excluded if they had a history of hepatic or renal disease, altered gastrointestinal motility, previous gastrointestinal surgery, gastrointestinal disease, or a contraindication to the use of morphine, codeine, tramadol, or paracetamol. Volunteers were also asked to declare that they did not take opioids or other regular medications.
The study used a double-blind, cross-over design. Gastric emptying was measured using the paracetamol absorption test (10). This test has been validated using radionuclide techniques that quantitatively measure gastric emptying (11). Volunteers attended four separate study sessions, each 2 wk apart. Treatments were randomized so that volunteers received either placebo (10 mL of 0.9% saline), tramadol 1.25 mg/kg (Searle, Division of Monsanto PLC, High Wycombe, Buckinghamshire, UK), codeine 1 mg/kg (Pharmacy Department, Queen's Medical Center, Nottingham, UK) or morphine 0.125 mg/kg (Evans Medical Ltd, Leatherhead, Surrey, UK) in 10 mL of 0.9% saline at each session. Volunteers were asked to refrain from taking any analgesics, food, or drink for 72, 6, and 3 h, respectively, before each session. At the beginning of each session, two IV cannulae were sited in each volunteer (one in each arm) using local anesthesia. One cannula was used to administer the trial drug, and the other was used for blood sampling. The investigator responsible for preparing the trial drugs took no other part in the trial; therefore, all other investigators and volunteers were blinded. The trial drug was given IV slowly over 5 min, and an initial 5-mL blood sample was taken after 20 min. Each volunteer then ingested paracetamol 1.5 g diluted in 200 mL of water (time = 0 min). Blood samples were also taken at 15, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300 , and 360 min. Volunteers were allowed food, drink, and limited mobility after 4 h. At other times, volunteers adopted a seated or semireclined position except during IV drug administration.
The total serum paracetamol concentration from each blood sample Serum paracetamol concentration-time data were plotted for each volunteer for each treatment. The areas under the curves between 0 and 360 min (AUCa& were calculated using the trapezoidal rule, and the peak serum paracetamol concentrations (Cmax) and the timing of Cmax (Tmax) were recorded. Overall comparisons of the concentration-time data, AUCO-360, Cmax, and Tmax were made using analysis of variance with or without repeated measures as appropriate. If these were statistically significant (P < 0.05), pairwise comparisons were made using the paired t-test. Statistical tests were performed using SPSS 7.5 for Windows 95 (SPSS UK Ltd, Chertsey, Surrey, UK).
Results
The mean (? SEM) age and weight for the six male and four female patients who took part in the study were 28 * 1 yr and 72 ? 4 kg, respectively. Of the 10 volunteers, 9 completed all sessions. After completing three sessions, one female volunteer had an allergic reaction to codeine phosphate and was withdrawn from this session. Another volunteer was given ondansetron for vomiting 4 h after receiving morphine.
Overall comparison of the concentration-time data demonstrated a statistically significant treatment effect (P = 0.002). * P < 0.05, t P < 0.01, and $ I' < 0.001 compared with saline. § P < 0.05, 11 P < 0.01, and 91 P < 0.001 compared with morphine.
Overall comparisons demonstrated statistically significant treatment effects for Cmax, Tmax, and AUCO-360 (P < 0.001, P = 0.003, and P = 0.049, respectively) ( Table 1 ). All three variables for morphine were significantly different compared with saline. Cmax and Tmax values for tramadol were smaller (16%) and greater (69%), respectively, compared with saline, but these differences were not statistically significant (P = 0.19 and P = 0.054, respectively).
All variables for tramadol were significantly different compared with morphine. The Tmax value for codeine was significantly greater than that for tramadol (P = 0.034).
Discussion
Morphine profoundly inhibits all variables of gastric emptying compared with saline. We therefore conclude that our study was valid. A clinical dose of IV tramadol had measurable but statistically insignificant effects on gastric emptying, consistent with a mild opioid-like effect. Although the clinical importance of this effect is difficult to evaluate, tramadol demonstrated a numerically smaller effect than both codeine (Tmax) and morphine (all variables). The use of tramado1 therefore may be associated with a lower risk of regurgitation and its sequelae than other opioids. Furthermore, the bioavailability of oral medication may be affected by opioids, with a possible reduction in drug efficacy. Conversely, there may also be a risk of gastric dumping and dangerous plasma concentrations with oral drugs given concurrently with opioid medication (1,12). Although these phenomena have not been evaluated adequately, in some postoperative patients, parenteral and oral tramadol may be less likely to alter drug kinetics than other opioids, such as morphine.
Clinically relevant doses of opioids were chosen; the dose of tramadol was approximately equianalgesic with morphine (13), the dose of codeine was less than equianalgesic and approximated the maximal parenteral dose used in clinical practice. It is therefore not surprising that codeine exhibited a smaller inhibitory effect on gastric emptying compared with morphine. Previous work in dogs demonstrated no delay in gastric emptying until a dose of 3 mg/kg was given (9).
Our results refer only to liquid ingestions, as the paracetamol absorption model does not estimate accurately gastric emptying of solids (14). However, other work using a scintigraphic technique to assess gastric emptying has demonstrated a small but statistically insignificant effect of multiple doses of oral tramado mg and codeine 60 mg on the emptying of a solid ingestion compared with placebo (15).
Evidence suggests that opioid-induced delay in gastric emptying has a peripheral mechanism (16). It is likely that the effect of different opioids on gastric emptying is related to the degree of opioid activity and, therefore, dose and affinity for opioid receptors. Tramadol has a weak affinity for p-opioid receptors, approximately lo-fold less than codeine and 6000-fold less than morphine (3). Furthermore, ~30% of its analgesic activity after a single dose in humans is from opioid receptor activati0n.l A mild effect on gastric emptying, minimal effects on the motility of other parts of the gut (6,15), and a lower incidence of other opioid receptor effects such as respiratory depression and constipation (4,18) are consistent with a lower magnitude of opioid system activity compared with morphine using equianalgesic doses.
Our findings are comparable to those of Murphy et al. (7), who evaluated the effect of IV tramadol (1 mg/kg) compared with saline on gastric emptying in 10 human volunteers using epigastric bioimpedante and the paracetamol absorption test. They concluded that there was a significant difference between tramadol and data from a retrospective control group receiving IV morphine (0.09 mg/kg) and that tramado1 does not significantly delay gastric emptying in humans. However, we demonstrated a measurable effect of tramadol on gastric emptying; in particular, a 69% increase in the mean time to Tmax. Our volunteers received a larger dose of tramadol, but the power of our study was insufficient to demonstrate a statistically significant effect of tramadol compared with saline, despite using a cross-over design. A retrospective calculation suggests that sample sizes of 12 and 14 EMPTYING 1998; 87:445-9 are required to demonstrate significant differences between tramadol and saline for Cmax and Tmax, respectively. However, the delay in Tmax may be of clinical importance because it is the magnitude of opioid effect on gastric emptying in the individual patient that is relevant. Although we did not study surgical patients, our results provide strong evidence that tramadol is likely to be associated with a significantly reduced risk of a delay in gastric emptying compared with morphine at clinical doses.
The physiology of gastric emptying is complex and involves myogenic, neural, and chemical control via the myenteric and submucous plexuses. These plexuses are affected by a variety of neurotransmitters, including serotonin, which controls gastric motility via a number of serotonin receptors that are yet to be fully elucidated (19) . Serotonin can also modulate the release of acetylcholine and other neurotransmitters (20). Prokinetic effects of serotonin on the stomach have been reproduced by inhibition of selective serotonin reuptake in humans (21). In contrast, circulating catecholamines have an inhibitory effect on gastric emptying (22), and increased noradrenaline release in response to painful stimuli may cause inhibition of gastric tone and emptying (23). Tramadol inhibits neuronal noradrenaline and serotonin reuptake and stimulates serotonin release (3). Therefore, the clinical effect of tramadol on gastric emptying may be determined by the relative contributions over time of both its p-opioid receptor and monoaminergic system actions. It is interesting to note that tricyclic antidepressant drugs, with monoaminergic actions similar to tramadol, delay gastric emptying (24). However, these drugs have additional anticholinergic activity, which is a potent inhibitor of gastric emptying.
Tramadol undergoes hepatic metabolism to a number of metabolites. One of these, 0-demethyl-tramadol (Ml) is active and has a greater affinity for the p-opioid receptor than the parent (25). Accumulation of the Ml metabolite may alter the clinical profile. For example, a patient with renal impairment and severe respiratory depression during regular oral tramadol therapy has been reported (26). This patient responded immediately to IV naloxone and required naloxone infusion for several hours to prevent recurrent respiratory depression and loss of consciousness. However, oral tramadol 100 mg four times daily for 2 days had no significant effect on gastric emptying or gut transit times as measured by using scintigraphy in healthy volunteers (14). We could find no data evaluating metabolite accumulation after parenteral tramado1 delivery in a clinical setting. It is of interest that the formation of the Ml metabolite is controlled by the polymorphic cytochrome CYP2D6 (25), which is also responsible for the bioactivation of codeine to morphine (27). The effect of cytochrome polymorphism on 
